📚 Hepatology — L8: Hepatic Tumors & Hcc

📚 Lecture Overview

This lecture covers hepatic tumors, focusing on the differential diagnosis, clinical presentation, imaging characteristics, and management of benign hepatic masses, cholangiocarcinoma, and hepatocellular carcinoma (HCC). Understanding these conditions is critical for clinicians to differentiate between benign lesions, bile duct cancers, and malignant primary liver tumors based on patient demographics, risk factors, and radiological hallmarks.

🎯 Key Concepts & Definitions

• Hepatic Hemangioma: The most common benign liver tumor, consisting of dilated vascular malformations that can grow with estrogen and progesterone exposure.
• Focal Nodular Hyperplasia (FNH): The second most common benign liver tumor, characterized by a central scar and a suspected hemodynamic disruption pathogenesis.
• Hepatic Adenoma (HA): The third most common benign liver tumor, strongly associated with oral contraceptive pills and anabolic steroids, carrying a risk of rupture and malignant transformation.
• Klatskin Tumor: A hilar cholangiocarcinoma located at the junction where the right and left hepatic ducts meet the common hepatic duct.
• Arterial Enhancement and Delayed Washout: The radiological hallmark of HCC on dynamic CT or MRI, characterized by hyperenhancement in the arterial phase followed by lower density relative to the liver in venous and delayed phases.
• Fibroblast Growth Factor Receptor 2 (FGFR2): Target proteins involved in cell growth that can mutate in intrahepatic cholangiocarcinoma, treatable with specific inhibitors like pemigatinib.

📖 Main Content

Benign Hepatic Tumors

• Hepatic Hemangiomas:
• Most common in middle-aged females.
• Features peripheral nodular enhancement with slow centripetal filling on contrasted studies.
• Lesions under 5 cm typically require no follow-up; rapidly growing lesions may need arterial embolization, radiotherapy, or resection.
• Focal Nodular Hyperplasia (FNH):
• Occurs mostly in adult females; features a central scar on gross examination.
• Contrast CT shows homogeneous arterial phase enhancement with a central non-enhancing scar.
• Resection is reserved for symptomatic patients or uncertain imaging.
• Hepatic Adenomas (HAs):
• Strongly linked to oral contraceptive pills, anabolic steroids, and glycogen storage disease.
• Lack bile ducts and ductules (differentiating them from FNH).
• HAs greater than 7 cm have a high bleeding risk due to fragility and require close monitoring or resection.

Cholangiocarcinoma (Bile Duct Cancer)

• Classification:
• Intrahepatic: Occurs within the liver bile ducts.
• Hilar (Klatskin tumor): Occurs just outside the liver at the bifurcation (most common type).
• Distal (Extrahepatic): Occurs near the small intestine.
• Risk Factors: Primary sclerosing cholangitis, older age (>50), inflammatory bowel disease, liver cirrhosis, choledochal cysts, cholecystitis, gallstones, and liver parasites (Opisthorchis viverrini and Clonorchis sinensis).
• Diagnosis: Imaging (Ultrasound, CT, MRI, MRCP), liver function tests, tumor markers (CA 19-9 and CEA), and biopsy via ERCP.
• Treatment & Targeted Therapies:
• Surgery (resection or liver transplant), biliary drainage, radiofrequency ablation, radiation, and chemotherapy (gemcitabine, cisplatin, 5-fluorouracil).
• FGFR2 inhibitors: Pemigatinib and futibatinib.
• Immunotherapy: PD-1 inhibitors (pembrolizumab, nivolumab) and checkpoint combinations.

Hepatocellular Carcinoma (HCC)

• Epidemiology & Risk Factors:
• Accounts for ~90% of primary liver cancers.
• Cirrhosis from any etiology is the strongest risk factor.
• Hepatitis B Virus (HBV): Integrates into the host genome, can cause HCC without cirrhosis.
• Hepatitis C Virus (HCV): RNA virus, does not integrate; risk is limited to those with cirrhosis/bridging fibrosis (cured by DAAs reducing risk by 50–80%).
• Other risks: NASH/diabetes, alcohol, aflatoxin B1 (synergistic with HBV), male predominance (2–3:1), and aging (>70).
• Protective factors: Coffee and aspirin.
• Histopathology:
• Trabecular architectural pattern is most common.
• Ranging from well-differentiated (small cells, minimal atypia) to poorly differentiated (large cells, hyperchromatic nuclei, pleomorphism).
• Clinical Presentation:
• Early-stage non-cirrhotic HCC is often asymptomatic.
• Cirrhotic-related HCC presents with decompensated liver failure signs; abdominal pain is the commonest presentation.
• Paraneoplastic syndromes: hypoglycemia, erythrocytosis, hypercalcemia.
• Diagnosis & Surveillance:
• Surveillance performed using Ultrasound every 6 months (doubling time is 6 months) combined with serum alpha-fetoprotein (AFP) (>20 ng/ml).
• Quadruple-phase CT or dynamic contrast-enhanced MRI for lesions ≥1 cm showing "arterial enhancement and delayed washout" (89% sensitivity, 96% specificity), which is diagnostic without biopsy.

📊 Visual Learning

💡 Important Points to Remember

• Hepatic hemangiomas are the most common benign tumor and display peripheral nodular enhancement with centripetal filling.
• Focal Nodular Hyperplasia (FNH) is distinguished by a central scar and persistent uptake on delayed/hepatobiliary phase MRI.
• Hepatic adenomas (HAs) are linked to oral contraceptives, lack bile ducts, and carry a severe rupture/bleeding risk if larger than 7 cm.
• Hilar cholangiocarcinoma (Klatskin tumor) is the most common form of bile duct cancer, strongly linked to Primary Sclerosing Cholangitis.
• CA 19-9 and CEA are key tumor markers for cholangiocarcinoma.
• HCC accounts for ~90% of primary liver cancers, with cirrhosis acting as the single strongest risk factor.
• HBV integrates into DNA (causing insertional mutagenesis and cancer even without cirrhosis), whereas HCV does not integrate (cancer risk is tied to developing cirrhosis/fibrosis).
• Aflatoxin B1 acts synergistically with HBV to spike HCC risk.
• HCC Surveillance interval is strictly 6 months using ultrasound and alpha-fetoprotein.
• Radiological hallmark of HCC: Arterial phase hyperenhancement and delayed washout (biopsy is NOT required if this hallmark is present on dynamic CT/MRI for at-risk patients).
• Coffee and aspirin have demonstrated a protective role against HCC development.

⚠️ Common Exam Questions

• Classic MCQ Trick: Examiners will describe a young female on oral contraceptives presenting with a liver mass and ask for the diagnosis. Distinguish carefully: if the lesion has a central scar and persistent hepatobiliary enhancement, it's FNH; if it lacks bile ducts, has high bleeding risk, and shows early arterial enhancement without late retention, it's a Hepatic Adenoma.
• Viral Carcinogenesis Trap: MCQs often test whether HBV and HCV integrate into the genome. Remember: HBV is a DNA virus that integrates, while HCV is an RNA virus that does not integrate (HCV-induced HCC strictly requires prior liver damage/cirrhosis).
• Diagnostic Criteria Trap: Questions may ask if a biopsy is mandatory to diagnose HCC. The correct answer is no, provided the lesion is ≥1 cm in an at-risk patient and displays the classic arterial wash-in and venous wash-out pattern on dynamic imaging.
• Tumor Markers: Do not confuse tumor markers. AFP is for HCC; CA 19-9 and CEA are for cholangiocarcinoma.

📝 Quick Review Checklist

I can differentiate hemangioma, FNH, and hepatic adenoma on imaging and risk factors
I understand the classification and primary risk factors of cholangiocarcinoma (Klatskin tumor)
I can list the key differences between HBV and HCV hepatocarcinogenesis
I know the exact surveillance protocol and interval for HCC (US + AFP every 6 months)
I can identify the radiological hallmark of HCC (arterial enhancement and delayed washout)
I understand the size threshold (7 cm) and bleeding risks associated with hepatic adenomas